|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From International Scientific Relations, Bayer, West Haven, CT.
Correspondence to: Glenn S. Tillotson, MSc, Director, International Scientific Relations, Bayer Corporation, 400 Morgan Lane, West Haven, CT 06516; e-mail: glenn.tillotson.b{at}bayer.com
Clinical practice guidelines are omnipresent and increasing in number; however, their utility and applicability are questioned. A great deal of effort is expended in their creation, but how they reach their ultimate customers is very variable. The pharmaceutical industry has considerable resources that may assist in this process; however, they need to be more involved in the development of clinical practice guidelines. This can happen only if both guideline developers and industry set aside their fears, concerns, and prejudices and collectively try to improve health care through more appropriate management of patients.
Key Words: data collection details dissemination
This article has been cited by other articles:
![]() |
K. Witt, E. Knudsen, S. Ditlevsen, and H. Hollnagel Academic detailing has no effect on prescribing of asthma medication in Danish general practice: a 3-year randomized controlled trial with 12-monthly follow-ups Fam. Pract., June 1, 2004; 21(3): 248 - 253. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |